Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Teucrium Wheat Fund — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Teucrium Wheat Fund trades at $23.81. The key difference: Teucrium Wheat Fund is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | WEAT | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $491.22 | $25.49 |
52-Week Low | $278.09 | $19.88 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
WEAT trades at $23.72, up 2.91% today, with a bullish technical signal from moving averages but neutral oscillators. The stock lacks disclosed financial ratios, and recent news highlights wheat price volatility and USDA production cuts affecting the agriculture sector. Support and resistance levels are tightly clustered around $23.
Outlook is influenced by commodity price swings and inflation trends, offering potential gains from wheat price increases but facing risks from supply adjustments and macroeconomic pressures. Investors should weigh sector-specific catalysts against inherent volatility in agricultural commodities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
